Related Experiment Video
Updated: Jun 13, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Presentation and risk stratification--improving prognosis for patients with multiple myeloma
1Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA. sloni01@emory.edu
Cancer Treatment Reviews
|May 18, 2010
Summary
Novel therapies and risk stratification show promise for improving multiple myeloma (MM) patient outcomes. While early data support this approach, large studies are needed for confirmation.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Multiple myeloma (MM) treatment has evolved significantly, with key milestones including chemotherapy, autologous stem cell transplant, and novel agents.
- Historically, treatment decisions were based on age and transplant eligibility, but risk stratification is now increasingly important.
- Advances in understanding MM's genetic and biological complexity drive the shift towards personalized treatment strategies.
Purpose of the Study:
- To review the evolution of multiple myeloma treatment strategies.
- To highlight the growing importance of risk stratification in guiding therapy selection.
- To assess the current evidence supporting the use of novel agents and risk stratification in MM management.
Main Methods:
- Review of historical treatment milestones in multiple myeloma.
- Analysis of the shift from age-based to risk-stratified treatment selection.
- Evaluation of current data on novel agents (thalidomide, lenalidomide, bortezomib, pegylated liposomal doxorubicin) in induction and maintenance therapy.
- Assessment of the role of cytogenetics and other risk stratification methods.
Main Results:
- Novel agents have significantly improved MM treatment options.
- Risk stratification using cytogenetics and other factors is becoming central to treatment decisions.
- Current data suggest that combining novel therapies with risk stratification may enhance patient prognosis.
- Early studies provide a rationale for risk-stratified treatment, despite a lack of large randomized trials.
Conclusions:
- The integration of novel therapies and risk stratification holds potential for improving multiple myeloma patient outcomes.
- Further large-scale, prospective randomized studies are essential to validate these findings and establish definitive treatment guidelines.
- Personalized treatment approaches based on biological understanding are crucial for advancing MM care.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...